Ortiz-Maldonado Gibson, ValentínFrigola, GerardEspañol Rego, MartaBalagué, OlgaMartínez Cibrian, NuriaMagnano, LauraGiné Soca, EvaPascal i Capdevila, MarionaCorrea, Juan G.Martínez Roca, AlexandraCid Vidal, JoanLozano Molero, MiguelVillamor i Casas, NeusBenítez-Ribas, DanielEsteve Comas, JordiLópez Guillermo, ArmandoCampo Güerri, EliasUrbano Ispizua, ÁlvaroJuan, ManelDelgado, Julio (Delgado González)2023-05-082023-05-082022-01-312234-943Xhttps://hdl.handle.net/2445/197660CART19 cells are emerging as an alternative therapy for patients with chronic lymphocytic leukemia (CLL). Here we report the outcome of nine consecutive patients with CLL treated with ARI-0001 CART19 cells, six of them with Richter’s transformation (RT). One patient with RT never received therapy. The cytokine release syndrome rate was 87.5% (12.5% grade ≥3). Neurotoxicity was not observed in any patient. All patients experienced absolute B-cell aplasia, and seven (87.5%) responded to therapy. With a median follow-up of 5.6 months, two patients with RT experienced a CD19-negative relapse. In conclusion, ARI-0001 cell therapy was feasible, safe, and effective in patients with high risk CLL or RT7 p.application/pdfengcc by (c) Ortiz Maldonado, Valentín et al., 2022http://creativecommons.org/licenses/by/3.0/es/Leucèmia limfocítica crònicaTeràpia cel·lularChronic lymphocytic leukemiaCellular therapyinfo:eu-repo/semantics/article2023-05-02info:eu-repo/semantics/openAccess929892535174095